in-PharmaTechnologist.com presents its latest round up of developments in drug delivery, including Philips first foray into drug delivery and a licensing deal for 3M.
The FDA is to extend its original review period for Exubera
(insulin (rDNA origin) powder for oral inhalation) by three months
to review additional technical chemistry data submitted by its
producers.
Animas has entered into a license and development agreement with
Debiotech, which aims to develop the next generation of insulin
pumps and micro needles using Debiotech's Micro Electromechanical
Systems (MEMS) microfluidic technology.
Germany's atugen, a specialist in RNA interference technologies for
switching off genes, has demonstrated the feasiblity of delivering
a small interfering RNA (siRNA)-based drug and achieving a
physiological response in animals.
A new inhaled formulation of insulin that could do away with the
need for diabetics to inject themselves before meals has been filed
for approval in Europe by Aventis and Pfizer and the dossier
accepted by the European Medicines Evaluation...